Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling. - Wikidata - thesis-toulmin - TriplyDB

Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling.

Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling.

http://www.wikidata.org/entity/Q34701183

about

Sclerostin and occlusion: A brief review The osteocyte as a therapeutic target in the treatment of osteoporosis Mutational analysis of sclerostin shows importance of the flexible loop and the cystine-knot for Wnt-signaling inhibition Promoting effect of 1,25(OH)2 vitamin D3 in osteogenic differentiation from induced pluripotent stem cells to osteocyte-like cells.High Bone Mass-Causing Mutant LRP5 Receptors Are Resistant to Endogenous Inhibitors In Vivo Crystallization and preliminary X-ray crystallographic analysis of the sclerostin-neutralizing Fab AbD09097.Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis.Sclerostin antibody treatment improves fracture outcomes in a Type I diabetic mouse model.Sclerostin inhibits osteoblast differentiation without affecting BMP2/SMAD1/5 or Wnt3a/β-catenin signaling but through activation of platelet-derived growth factor receptor signaling in vitro Multiple myeloma in the marrow: pathogenesis and treatments.Sclerostin antibody prevented progressive bone loss in combined ovariectomized and concurrent functional disuse.The sclerostin-neutralizing antibody AbD09097 recognizes an epitope adjacent to sclerostin's binding site for the Wnt co-receptor LRP6 The skeletal cell-derived molecule sclerostin drives bone marrow adipogenesis.Current trends in bone tissue engineering.Connecting Bone and Fat: The Potential Role for Sclerostin.The Microdamage and Expression of Sclerostin in Peri-implant Bone under One-time Shock Force Generated by Impact.Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer.Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.SOST/Sclerostin Improves Post Traumatic Osteoarthritis and Inhibits MMP2/3 Expression After Injury.The relationship between postmenopausal women's sclerostin levels and their bone density, age, body mass index, hormonal status, and smoking and consumption of coffee and dairy products.Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction.

P2860

Q26830392-5BF9DA9D-4F5F-44BD-8EF6-008DB8CF7A83 Q27009129-39D0808D-8414-4892-B6F4-454C989D4D26 Q28535490-A5ED2567-F8E6-41AD-8946-7CF15F717CA6 Q35133864-61A5222F-2720-41B6-B8CF-FFAB7D892497 Q35586766-C374B492-0B63-42DE-966D-9583109F1E5F Q35596559-8F9068C9-FA42-4A6E-8EC1-F10FDAEDA5FA Q35694436-6BFF5E1D-E75C-4F03-93BD-E899E0E561A7 Q36253807-1A60467B-B5E7-476F-A9A0-80BA129E8FF3 Q36256294-81526FE8-9CC3-4C53-BD5B-C2A4C546DE4E Q36725401-25D4EEA7-C50C-4773-B202-8C559EA94F23 Q36889104-4C9777EA-1B79-47FE-AA6A-CC521CCD99C2 Q37224687-77DF9DAB-7042-444A-844F-8FB5CEB2E18C Q38810794-6CDD4229-4B03-4BD9-9342-8127111A1BAC Q38923797-F9B64025-076E-4BC2-878A-E82A1A5B8472 Q39350147-2007F47B-0587-4A3C-95D4-0EF29608AD39 Q41140478-DEFD615D-FC86-4A40-A217-3FD3ED40374A Q41194152-17F41C02-35F2-41C2-8CA0-28BA442A8ED8 Q47894997-8ECC68E1-75D1-4F04-B74D-EC319C41E9FB Q49610005-AD1C4F3B-32BF-476F-AA08-8719A8840625 Q51161134-31002787-0A22-48F3-AAF4-0BB48374D378 Q55025334-2AB2A42C-5694-46D1-B778-88483931BBBE

P2860

Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling.

http://www.wikidata.org/entity/Q34701183

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Anti-Sclerostin antibody inhib ...... agonism of Wnt/LRP6 signaling.

@ast

Anti-Sclerostin antibody inhib ...... agonism of Wnt/LRP6 signaling.

@en

Anti-Sclerostin antibody inhib ...... agonism of Wnt/LRP6 signaling.

@nl

type

label

Anti-Sclerostin antibody inhib ...... agonism of Wnt/LRP6 signaling.

@ast

Anti-Sclerostin antibody inhib ...... agonism of Wnt/LRP6 signaling.

@en

Anti-Sclerostin antibody inhib ...... agonism of Wnt/LRP6 signaling.

@nl

prefLabel

Anti-Sclerostin antibody inhib ...... agonism of Wnt/LRP6 signaling.

@ast

Anti-Sclerostin antibody inhib ...... agonism of Wnt/LRP6 signaling.

@en

Anti-Sclerostin antibody inhib ...... agonism of Wnt/LRP6 signaling.

@nl

P1433

Q34701183-856FC225-3632-4674-997A-30E9AA6CA37C

P1476

Q34701183-63E82DD4-4879-4F0A-A870-FBA6325C5259

P2093

Q34701183-081326AB-539F-4574-8363-686961084BE5

Q34701183-0C303922-CE61-40C3-8C02-CB3690C94582

Q34701183-1D20A721-E420-4F93-8F4B-914C2E23577F

Q34701183-22F82F7A-D605-4BC8-94E8-1961AC34EDAB

Q34701183-4A34E006-741A-4EFA-B772-1B50AC9A655F

Q34701183-5B2473DB-5338-415E-9099-C7F5FFBB6B6D

Q34701183-69D8CBC3-6CDA-440A-8D2F-3746DC9C234B

Q34701183-75D4BBDD-E4B5-43FC-BAFF-740FD1037ABA

Q34701183-809366A9-5CE8-4262-8015-05480EFD80AD

Q34701183-A80EACA2-3459-43E6-A8B7-FD7D4E236E51

P2860

Q34701183-0C794668-23FA-452B-9F32-D7AE7861EE2F

Q34701183-1A5CDBA7-D964-4311-B557-F96C758DE43A

Q34701183-1C52D3DC-FF70-4DED-85E4-843709B4F275

Q34701183-1CA9E78C-F1E6-4E47-A797-D46232D6A5D8

Q34701183-2BCE58A6-B239-4538-8699-D2A6E23D5BF6

Q34701183-2E5E4560-D4E7-4664-8A4C-D1B192D9449D

Q34701183-2F78C30D-D28D-4DC6-A987-6E933A5D80C4

Q34701183-37375802-D8F6-4902-BBFA-B73977F1B116

Q34701183-404537CB-D8D4-47C3-8103-3871C0B61633

Q34701183-47764EFE-7D8D-4D06-B02B-637770C1C14B

P304

Q34701183-9C109739-68B9-4588-BC28-AD901AF512C0

P31

Q34701183-33694656-FBAE-4058-9843-CCD94EB017FB

P356

Q34701183-3020CE2B-E8C3-4908-9B75-883377CCA5BA

P407

Q34701183-E7D64477-F3EB-42BA-9BA1-9C55380FDC71

P433

Q34701183-D7D65F5D-38EA-4B51-B810-AF5C3EA76FEF

P478

Q34701183-BE9EBE9F-955B-44F8-B521-49547578AD51

P577

Q34701183-95DFF6DC-FE77-4A66-B486-CF7D4EFA815B

P5875

Q34701183-168E2FC8-BCB8-49E3-9FE1-89C50E1E46B2

P698

Q34701183-06B86B43-18F5-4854-A1E7-63286DAAAA8A

P921

Q34701183-2C879E14-2F23-4B16-9005-F6C7FF935C5D

P932

Q34701183-20AFB14F-22DD-468F-AC82-0F8F5C6E2A7B

P356

JOURNAL.PONE.0062295

P1433

P1476

Anti-Sclerostin antibody inhib ...... agonism of Wnt/LRP6 signaling.

@en

P2093

Achim Knappik

http://www.w3.org/2001/XMLSchema#string

Christian Frisch

http://www.w3.org/2001/XMLSchema#string

David J J de Gorter

http://www.w3.org/2001/XMLSchema#string

Eva-Maria Muth

http://www.w3.org/2001/XMLSchema#string

Juan Zhang

http://www.w3.org/2001/XMLSchema#string

Maarten van Dinther

http://www.w3.org/2001/XMLSchema#string

Peter ten Dijke

http://www.w3.org/2001/XMLSchema#string

Puck B van Kasteren

http://www.w3.org/2001/XMLSchema#string

Stella E Weidauer

http://www.w3.org/2001/XMLSchema#string

Thomas D Mueller

http://www.w3.org/2001/XMLSchema#string

P2860

LDL-receptor-related proteins in Wnt signal transduction

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow

Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6

Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

Regulation of Wnt/LRP signaling by distinct domains of Dickkopf proteins.

A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait

P304

e62295

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0062295

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236604419

http://www.w3.org/2001/XMLSchema#string

P698

23638027

http://www.w3.org/2001/XMLSchema#string

P921

P932

3639248

http://www.w3.org/2001/XMLSchema#string